Comparing ticagrelor and prasugrel for heart disease treatment
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study
This study is testing whether ticagrelor or prasugrel is better at preventing bleeding and heart issues in patients with heart disease who have already been on another type of treatment.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 48 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06691191 on ClinicalTrials.gov |
What this trial studies
This study aims to compare the effectiveness of ticagrelor and prasugrel as single antiplatelet therapies after patients have undergone dual antiplatelet therapy for coronary artery disease. It will evaluate the pharmacodynamic profiles of both medications to determine if they are comparable in reducing bleeding events without increasing the risk of heart-related complications. The study will involve patients aged 18 to 75 who have been on dual antiplatelet therapy for at least 90 days following a percutaneous coronary intervention. Participants will be randomly assigned to receive either ticagrelor or prasugrel for the duration of the study.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 who have been on dual antiplatelet therapy for at least 90 days after a percutaneous coronary intervention.
Not a fit: Patients with a history of stent thrombosis, recent PCI, or those over 75 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify a safer and more effective antiplatelet therapy for patients with coronary artery disease.
How similar studies have performed: Previous studies have shown success with similar approaches, particularly with ticagrelor monotherapy demonstrating reduced bleeding events without increasing ischemic risk.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI. 2. Age between 18 and 75 years old 3. Able to provide written informed consent Exclusion criteria: 1. Prior history of stent thrombosis 2. PCI within 90 days. 3. History of stroke/TIA 4. Age \> 75 years old 5. Weight \< 60 kg 6. History of intracranial hemorrhage 7. On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis) 8. Patients with known coagulation disorders 9. Known severe hepatic impairment 10. Hypersensitivity to prasugrel or ticagrelor 11. Pregnant and breastfeeding persons \[persons of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\]. If the potential subject is a person of childbearing potential, a pregnancy test will be done. If the subject is pregnant, participation in this study will end.
Where this trial is running
Jacksonville, Florida
- University of Florida Jacksonville — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Francesco Franchi, MD — University of Florida College of Medicine Jacksonville
- Study coordinator: Francesco Franchi, MD
- Email: francesco.franchi@jax.ufl.edu
- Phone: 9042445515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.